Author

Meng-Jie Dong

h-index 1 View on Semantic Scholar

We have 3 of 14 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

161Tb Radiopharmaceutical Therapy as a Treatment for RANKL-Positive Multiple Myeloma.

BACKGROUND Denosumab, an anti-RANKL monoclonal antibody, is clinically approved for bone protection in multiple myeloma (MM) but lacks direct cytotoxic effects on tumor cells. Herein, we repurpose this well-tolerated antibody as a targeted delivery vehicle by conjugating it with the emerging radionuclide 161Tb, which e...

Hao-Yi Yan, Jun Li, Chuan-Mian Xu et al. · European Journal of Pharmace... · 0 citations

Open access Aug 2026

Longitudinal plasma phosphorylated tau217 classification and the association with Alzheimer's disease progression

Longitudinal diagnostic and prognostic validity of plasma phosphorylated tau217 (p‐tau217) in Alzheimer's disease (AD) remains uncertain.

Guo-Yu Lan, Wang Liao, Mingxing Jiang et al. · Alzheimer's & Dementia · 0 citations

Aug 2026

Cross-Sectional and Longitudinal Diagnostic Performance of Plasma p-tau217 and p-tau217/Aβ42 in Alzheimer's Disease.

OBJECTIVE Recent studies suggest that combining plasma phosphorylated tau (p-tau) with β-amyloid (Aβ) may improve diagnosis accuracy for Alzheimer's disease (AD). However, the cross-sectional and longitudinal concordance of these markers with Aβ positron emission tomography (PET) positivity remains incompletely underst...

Mingxing Jiang, Guo-Yu Lan, Jiayi Zhu et al. · Annals of Neurology · 0 citations